PD-1 jointly developed by Yuheng pharmaceutical and Yaoming biology was approved for listing
Financial Associated Press, August 30 - on August 30, the official website of the State Food and drug administration showed that the anti-PD-1 whole person innovative antibody drug cyprimab (gls-010) jointly developed by Yuheng pharmaceutical / Yaoming biology has been approved by nmpa to be listed for the treatment of patients with recurrent or refractory classic Hodgkin's lymphoma (R / R CHL) above the second line. This is the sixth domestic PD-1 mAb approved by nmpa.
This text is a result of machine translation.
Related companies：
In-depth
Briefing Mar 13, 2022 08:49 PM
· Financials
Capital group, an asset management institution, launched ETF products for the first time: buying Chinese stocks such as Guizhou Maotai, Yaoming biology and meituan
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing Feb 08, 2022 03:30 PM
· Healthcare
Yaoming biological was included in the "unverified list" in the United States, and its share price plummeted
Healthcare
Biotech Astrabio Nets Nearly CNY 100 Mn in Series A financing Round
Astrabio, specializing in the Single Molecule Counting technology, will continue to promote the revolution of the next-generation immunoassay technology by further accelerating the R&D and clinical translation of new biomarkers with the fresh proceeds.
Updated 5 hours ago
Healthcare
Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Jun 28, 2022 10:58 PM
Briefing Feb 07, 2022 08:09 AM
· Healthcare
The battery plant jointly built by SK innovation and Ford was started in December last year
See more
Read next
In-depth
In-depth
In-depth
Technology
A Closer Look at China’s Cloud Service Market, Guessing Who Will Succeed? [1/2]
Jun 27, 2022 05:09 PM
In-depth
Healthcare
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
Jun 27, 2022 12:24 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.